Related Experiment Video
Updated: Jul 10, 2026

10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Immunoglobulin D lambda multiple myeloma and amyloidosis with predominant soft tissue involvement
Gulistan Bahat1, Nilgun Erten, Bulent Saka
1Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. gbahatozturk@yahoo.com
Summary
Multiple myeloma, a cancer of plasma cells, can involve amyloidosis. This case highlights a rare IgD lambda myeloma presenting with unusual mucocutaneous and joint amyloidosis, not typical kidney or heart issues.
Area of Science:
- Hematology
- Oncology
- Nephrology
Background:
- Multiple myeloma (MM) affects approximately 15% of patients with amyloidosis.
- Nephrotic syndrome, cardiomyopathy, and peripheral neuropathy are common manifestations.
- Amyloid arthropathy is an infrequent clinical feature of MM-associated amyloidosis.
Observation:
- This report details a patient with immunoglobulin D (IgD) lambda type MM.
- The patient presented with mucocutaneous amyloidosis and amyloid arthropathy.
- Notably, the patient showed no signs of nephrotic syndrome or cardiomyopathy.
Findings:
- The case illustrates a rare IgD myeloma with an unusual organ distribution of amyloid.
- Amyloid arthropathy and mucocutaneous involvement were the primary clinical features.
- Absence of cardiac or renal involvement deviates from typical MM-amyloidosis presentations.
Implications:
- This case expands the understanding of clinical heterogeneity in IgD myeloma.
- It underscores the importance of considering rare organ involvements in MM-associated amyloidosis.
- Highlights the diagnostic challenge posed by unusual presentations of rare myeloma subtypes.
Related Concept Videos
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...